PMC:3724972 / 15012-15664 JSONTXT

{"project":"2_test","denotations":[{"id":"23673515-15126577-63233629","span":{"begin":182,"end":184},"obj":"15126577"},{"id":"23673515-11444429-63233630","span":{"begin":186,"end":188},"obj":"11444429"},{"id":"23673515-18642088-63233631","span":{"begin":354,"end":356},"obj":"18642088"},{"id":"23673515-11249538-63233632","span":{"begin":648,"end":650},"obj":"11249538"}],"text":"Like somatostatin receptors, dopamine receptors are widely expressed in normal neuro-endocrine tissues and pituitary adenomas, including approximately 80 % of corticotroph adenomas [48, 49]. Five dopamine receptor subtypes have been characterized, usually classified as D1-like or D2-like, with most D2-like receptors associated with inhibitory actions [50]. The dopamine agonists bromocriptine and cabergoline have both been used to treat pituitary adenomas; however, cabergoline is more selective at D2 receptors and has been found to be more effective and better tolerated than bromocriptine in women receiving treatment for hyperprolactinemia [51]."}